Journal Watch · Nature Biotechnology · 2026

Engineered living glues secrete therapeutic proteins for treatment of inflammatory bowel disease.

Additionally, the treatment decreases intestinal inflammation, promotes mucosal repair and restores gut barrier integrity, demonstrating comprehensive therapeutic efficacy.

Ge C, Jiang S, Dong X et al.Nature Biotechnology3 min readPharma relevance 40/100

DOI: 10.1038/s41587-025-02970-9PMID: 41555021Study type: preclinical (animal / model) study

TL;DR

Additionally, the treatment decreases intestinal inflammation, promotes mucosal repair and restores gut barrier integrity, demonstrating comprehensive therapeutic efficacy.

Key findings

  • Using two mouse models of IBD, the colitis model induced by dextran sulfate sodium and the interleukin-10-knockout mouse model, we demonstrate improved weight recovery, reversed colonic shortening and reduced intestinal bleeding.
  • Additionally, the treatment decreases intestinal inflammation, promotes mucosal repair and restores gut barrier integrity, demonstrating comprehensive therapeutic efficacy.

Numbers at a glance (from the abstract)

or 7

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

Adhesive production enables sustained bacterial attachment to inflamed tissues for up to 10 days or 7 days following a single rectal or oral administration, respectively. This effect depends on bleeding-induced adhesion.

Full abstract (original)

Background: Engineering bacteria to secrete gut therapeutics has been limited by their poor autonomous sensing of pathological cues and inability to sustain localized, long-term therapeutic activity. Here we engineer nonpathogenic Escherichia coli with a blood-inducible gene circuit that secretes the barnacle-derived adhesive protein CP43K and the therapeutic gut-barrier-healing factor TFF3 in response to gastrointestinal bleeding, an indicator of severe inflammatory bowel disease (IBD).

What they did: Adhesive production enables sustained bacterial attachment to inflamed tissues for up to 10 days or 7 days following a single rectal or oral administration, respectively. This effect depends on bleeding-induced adhesion.

Results & conclusions: Using two mouse models of IBD, the colitis model induced by dextran sulfate sodium and the interleukin-10-knockout mouse model, we demonstrate improved weight recovery, reversed colonic shortening and reduced intestinal bleeding. Additionally, the treatment decreases intestinal inflammation, promotes mucosal repair and restores gut barrier integrity, demonstrating comprehensive therapeutic efficacy.

Abstract © the authors / Nature Biotechnology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41587-025-02970-9 · PubMed 41555021.

Why it matters for pharma & biotech

  • Relevant to Biology & Life Sciences teams tracking Nature Biotechnology for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.

Frequently asked questions

What did this Nature Biotechnology study find?

Additionally, the treatment decreases intestinal inflammation, promotes mucosal repair and restores gut barrier integrity, demonstrating comprehensive therapeutic efficacy.

What type of study is this?

It is a preclinical (animal / model) study, published in Nature Biotechnology in 2026. Adhesive production enables sustained bacterial attachment to inflamed tissues for up to 10 days or 7 days following a single rectal or oral administration, respectively.

Where can I read the original paper?

The original is at the publisher via DOI 10.1038/s41587-025-02970-9. PubMed ID: 41555021. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Ge C, Jiang S, Dong X et al.. Engineered living glues secrete therapeutic proteins for treatment of inflammatory bowel disease.. Nature Biotechnology (2026). DOI: 10.1038/s41587-025-02970-9.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/engineered-living-glues-secrete-therapeutic-proteins-for-treatment-of-in-029709/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides